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     Despite the many advantages of small interfering RNA (siRNA) inhalation therapy and a growing 
prevalence of respiratory pathologies, its clinical translation is severely hampered by inefficient 
intracellular delivery. To this end, we previously developed hybrid nanoparticles consisting of an siRNA-
loaded nanosized hydrogel core (nanogel) coated with Curosurf®, a clinically used pulmonary surfactant 
(PS). Interestingly, the PS shell was shown to markedly improve particle stability as well as intracellular 
siRNA delivery in vitro and in vivo. The major aim of this work was to identify the key molecular 
components of PS responsible for the enhanced siRNA delivery and evaluate how the complexity of the 
PS coat could be reduced. We identified surfactant protein B (SP-B) as a potent siRNA delivery 
enhancer when reconstituted in proteolipid coated hydrogel nanocomposites. Improved cytosolic siRNA 
delivery was achieved by inserting SP-B into a simplified phospholipid mixture prior to nanogel coating. 
This effect was observed both in vitro (lung epithelial cell line) and in vivo (murine acute lung injury 
model), albeit that distinct phospholipids were required to achieve these results. Importantly, the 
developed nanocomposites have a low in vivo toxicity and are efficiently taken up by resident alveolar 
macrophages, a main target cell type for treatment of inflammatory pulmonary pathologies. Our results 
demonstrate the potential of the endogenous protein SP-B as an intracellular siRNA delivery enhancer, 
paving the way for future design of nanoformulations for siRNA inhalation therapy. 
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Pathologies of the respiratory tract are subject to a growing prevalence and for many of these 
illnesses an unmet therapeutic need exists. According to the latest report of the World Health 
Organization, chronic obstructive pulmonary disease, lower respiratory infections and lung cancer are 
among the top five leading causes of death worldwide. [1] To address this major global health problem, 
novel and efficient therapies are urgently needed.  
Over the past two decades, research in the field of RNA interference (RNAi) has created new 
therapeutic opportunities. Activation of the RNAi pathway in the cytosol of affected cells, e.g. by small 
interfering RNA (siRNA), enables the specific post-transcriptional silencing of key molecular disease 
targets. As the expression of virtually all genes is susceptible to silencing by siRNAs, new therapeutic 
targets have emerged that are not readily druggable by conventional small molecules. [2],[3] The lung 
is an attractive target organ for siRNA therapeutics, since it offers the possibility for non-invasive local 
administration. Inhalation therapy with siRNA (i) enables direct and prolonged contact with pulmonary 
cells, (ii) limits systemic exposure, (iii) lowers the required therapeutic dose and (iv) allows for self-
administration, resulting in a better patient compliance. [4] Unfortunately, despite these advantages, still 
many extra- and intracellular barriers limit the siRNA dose that effectively reaches the cytosol of the 
target cells. [5] To guide siRNA across these biological barriers, many research groups attempt to 
formulate siRNA into synthetic polymer- or lipid-based nanoparticles (NPs).  
However, such NPs often fail to merge efficient siRNA delivery with biocompatibility, [6-8] 
rationalizing the growing interest in the application of bio-inspired materials for drug delivery. In this 
context, we recently reported on hybrid NPs composed of an siRNA-loaded polymeric matrix core that 
is coated with a proteolipid shell of Curosurf®, a clinical pulmonary surfactant (PS). [9],[10] The core of 
these NPs consists of a cationic polysaccharide hydrogel nanoparticle (nanogel; NG), which has a high 
loading capacity for siRNA (~0.4 µg/µg) and a proven delivery potential in various cell types. [11-13] PS 
is an endogenous surface-active material that covers the alveolar surface to maintain a low surface 
tension upon expiration and prevent alveolar collapse. In the context of siRNA delivery, PS is primarily 
regarded as an important extracellular barrier in the deep lung that limits access to underlying cells upon 
inhalation therapy. [14],[15] Nonetheless, we observed that a PS outer layer around siRNA loaded NGs 
(siNGs), although hampering cellular uptake, significantly enhanced intracellular siRNA delivery in lung 
cell types in vitro and in vivo (Scheme S1). However, the molecular determinants for this delivery-
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promoting effect remain elusive. [9],[10] Native PS is composed of various lipids (~90 wt%) and 
specialized surfactant proteins (SPs, ~10 wt%). [16] The lipid fraction mainly consists of 
phosphatidylcholine (PC) (~60-70 wt%) and anionic phospholipids such as phosphatidylglycerol (PG) 
and phosphatidylinositol (~10-15 wt%) species. Among PC lipids, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) represents ~40-50 wt% of the total surfactant mass. DPPC is essential to 
sustain the required low surface tension during expiration. The negatively charged PG is believed to 
promote interaction with surfactant protein B (SP-B) and surfactant protein C (SP-C), both cationic and 
hydrophobic. Although required for the endogenous biological activity of pulmonary surfactant, we 
hypothesize that many of these components are redundant in the context of cellular delivery of siRNA. 
Therefore, the aim of this work was to identify the key constituents in PS that are responsible for the 
enhanced cytosolic siRNA delivery. Hereto, siNGs were layered with a PS-inspired proteolipid coat of 
varying composition. The impact on siRNA delivery was tested both in vitro in non-small cell lung cancer 
cells (H1299) and in vivo in a murine lipopolysaccharide-induced acute lung injury model, using an 
siRNA to target tumor necrosis factor (TNF) α. We found that the siRNA delivery promoting effect was 
governed by SP-B, for which the extent of the effect depends on the phospholipid environment in which 
it is embedded. This knowledge could serve as a basis for future rational design of novel pulmonary 
















2. MATERIALS & METHODS 
2.1. Small interfering RNAs  
For in vitro experiments, 21 nucleotide (nt) small interfering RNA (siRNA) duplexes targeted against 
Enhanced Green Fluorescent Protein (eGFP), hereafter abbreviated as siEGFP and non-targeting 
negative control duplexes (siCTRL), were purchased from Eurogentec (Seraing, Belgium). For siEGFP: 
sense strand = 5´-CAAGCUGACCCUGAAGUUCtt-3´; antisense strand =  
5´-GAACUUCAGGGUCAGCUUGtt-3´. For siCTRL: sense strand =  
5´-UGCGCUACGAUCGACGAUGtt-3´; antisense strand = 5´-CAUCGUCGAUCGUAGCGCAtt-3´ 
(capital letters represent ribonucleotides; lower case letters represent 2´-deoxyribonucleotides). For 
fluorescence experiments, the siCTRL duplex was labeled with a Cy®5 dye at the 5’ end of the sense 
strand (siCy5). The fluorescent modifications were performed and verified by Eurogentec. The 
concentration of the siRNA stock solutions in nuclease-free water (Ambion®-Life Technologies, Ghent, 
Belgium) was calculated from absorption measurements at 260 nm (1 OD260 = 40 µg/mL) with a 
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, DE, USA). For in vivo experiments, 
stabilized 21 nt siRNA duplexes (siSTABLE), targeted against murine tumor necrosis factor (TNF) α, 
hereafter abbreviated as siTNFα, and non-targeting negative control duplexes (siCTRL) were purchased 
from GE Healthcare Dharmacon (Diegem, Belgium). The used siTNFα was selected from a set of four 
proposed sequences as provided by the manufacturer, by testing TNFα knockdown for all sequences in 
vitro (Figure S1) using the TNF alpha Ready-SET-Go!® ELISA assay (eBioscience, San Diego, CA, 
USA). siTNFα sense strand = 5'-CAAAUGGCCUCCCUCUCAUUU-3'; antisense strand =  
5'-AUGAGAGGGAGGCCAUUUGUU-3’. The sequence of stabilized siCTRL was confidential and could 
not be listed. 
2.2. Synthesis of dextran nanogels and loading with siRNA 
Cationic dextran nanogels were prepared using an inverse miniemulsion photopolymerization 
method as reported previously. [11] Briefly, 150 mg of dextran hydroxyethyl methacrylate (dex-HEMA) 
with a degree of substitution of 5.2 [33] was dissolved in a solution containing 97.5 μL Irgacure 2959 (10 
mg/mL in water; Sigma-Aldrich, Bornem, Belgium) as UV curing photoinitiator, 180 μL nuclease-free 
water and 195 μL of a cationic methacrylate monomer, [2-(methacryloyloxy)-ethyl] trimethylammonium 
chloride (TMAEMA, 80 wt% solution in water; Sigma-Aldrich). The obtained dex-HEMA solution was 
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emulsified in 5 mL of mineral oil (Sigma-Aldrich), supplemented with the surfactant ABIL EM 90 (0.5 mL) 
(Evonik Goldschmidt GmbH, Essen, Germany), through ultrasonication (90 s, amplitude 15 %; Branson 
Digital Sonifier®, Danbury, USA). The formed emulsified nanodroplets were immediately cross-linked by 
UV irradiation (900 s, Bluepoint 2.1 UV source, Hönle UV technology, Gräfelfing, Germany) under 
cooling (4 °C). The resulting dex-HEMA-co-TMAEMA nanogels, hereafter abbreviated as NGs, were 
collected by precipitation in acetone and washed 4 times with acetone:hexane (1:1). Traces of organic 
solvent were removed by vacuum evaporation and the pellet was redispersed in 5 mL nuclease-free 
water. To assure long-term stability, the NGs were lyophilized and stored desiccated. To obtain siRNA-
loaded NGs (siNGs) for in vitro experiments, a NG stock (2 mg/mL) was prepared by dispersing a 
weighed amount of lyophilized particles in ice-cooled nuclease-free water, followed by brief sonication 
(3 x 5 s, amplitude 10 %; Branson Digital Sonifier®, Danbury, USA). Subsequently, equal volumes of 
NG and siRNA dilutions in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (pH 7.4, 
20 mM) were mixed and incubated at 4 °C for ≥ 15 min to allow electrostatic complexation. For in vivo 
experiments, a NG stock (10 mg/mL) was prepared as described above. The NG stock contained less 
than 0.5 EU/mL lipopolysaccharide (LPS) as determined by the Endosafe®-PTS™ assay (Charles River 
International, Lecco, Italy). NGs and siRNAs were diluted in nuclease-free water prior to mixing and 
incubation. In addition, all preparative steps for the in vivo experiments were performed with LPS-free 
materials under LPS-free conditions. The concentration of siRNA dilutions used for NG loading was 
adjusted according to the intended dose. 
2.3. Isolation, analysis and quantification of hydrophobic surfactant proteins 
The isolation of SP-B and SP-C from native porcine pulmonary surfactant or Curosurf® (a 
commercially available porcine pulmonary surfactant preparation; Chiesi Farmaceutici, Parma, Italy) 
was performed as described earlier by Pérez-Gil and coworkers. [34] For extraction from native porcine 
lungs, the lungs were first minced and carefully washed. Next, the mixture was filtered and centrifuged 
(1000 g at 4 °C for 15 min). The supernatant was again centrifuged (3000 g at 4 °C for 2 h) and from 
the isolated pellet, enriched in large lipid/protein PS complexes, the hydrophobic components including 
lipids and hydrophobic surfactant proteins were extracted with chloroform/methanol mixtures according 
to the Bligh & Dyer method. Chromatographic separation in Sephadex LH-20 (GE Healthcare, 
Machelen, Belgium) of the organic extract allowed separating the hydrophobic protein fraction from the 
surfactant lipid fractions. A subsequent chromatographic step in Sephadex LH-60 yielded purification of 
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SP-B and SP-C, which were stored in chloroform/methanol solutions. Phospholipid contamination of the 
protein samples was quantified by phosphorus determination as described by Rouser et al. [35] Purity 
and nature of isolated pools of proteins were analyzed by sodium dodecyl sulfate (SDS) electrophoresis 
in polyacrylamide gels and subsequent western blot with anti-SP-B and anti-SP-C primary antibodies 
(Seven Hills, Cincinnati, OH, USA). The quantification of the amount of  isolated SP-B and SP-C was 
performed by an amino acid analysis. 
 
2.4. Preparation of Curosurf® coated siRNA-loaded nanogels 
Prior to the formation of the Curosurf® pulmonary surfactant coat, the NGs were loaded with siRNA, 
as described above. The unprocessed Curosurf® dispersion (80 mg/mL) was diluted to 4.5 mg/mL in 
HEPES buffer and incubated with siNGs in equal volumes for 10 min at 4 °C, using a Curosurf® to NGs 
weight ratio of 15 mg/mg. Subsequently, the surfactant coat on the siNGs was formed by sonication (3 
x 10 s, amplitude 10 %; Branson Digital Sonifier®, Danbury, USA). This resulted in a hybrid nanoparticle 
as described earlier,  [9] further denoted as Curosurf® coated siNGs.  
 
2.5. Preparation of proteolipid coated siRNA-loaded nanogels 
The following phospholipids were used for siNG coating: 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), L-α-
phosphatidylglycerol (eggPG), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC). All 
phospholipids were purchased from Avanti Polar Lipids, Inc. (AL, USA). The phospholipids were mixed 
in chloroform at different weight ratios, specified in every figure caption and listed in Table S1. In order 
to incorporate SP-B and/or SP-C in the phospholipid outer layer, the isolated hydrophobic proteins were 
combined with the phospholipids in chloroform at indicated concentrations. A (proteo)lipid film was 
formed by rotary evaporation of the organic solvent under vacuum at 37 °C. The dried (proteo)lipid film 
was rehydrated in HEPES buffer by mechanical agitation, resulting in a final (proteo)lipid concentration 
of 4.5 mg/mL. The hydrated (proteo)lipid film was used in the coating procedure, as described above, 
for which the ratio of the (proteo)lipid mixture to NGs was 15 mg/mg (in vitro experiments) or 10 mg/mg 
(in vivo experiments). The (proteo)lipid-siNG mixtures for in vivo administration were diluted 2-fold in 
nuclease-free water prior to sonication. This resulted in a hybrid nanoparticle further denoted as 
proteolipid coated siNGs. Hydrodynamic diameter and zeta-potential of all formulations were determined 
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via Dynamic Light Scattering (DLS) (Zetasizer Nano, Malvern Instruments, Worcestershire, United 
Kingdom). All formulations were imaged using transmission electron cryomicroscopy (cryoTEM). 3.5 μL 
of every sample was applied to a 300 mesh quantifoil grid (1/3.5) and incubated for 30 s. Next, grids 
were mounted in a plunge-freezer (EMBL), blotted one-sided for 3 s using a Whatman 1 filter paper and 
plunged into liquid ethane at a temperature of −180 °C, followed by storage in liquid nitrogen until 
observation. Next, the samples were transferred to a Gatan 914 cryoholder and imaged at low dose 
conditions at −177 °C, using a JEOL JEM1400 TEM equipped with an 11 Mpxl Olympus SIS Quemesa 
camera. All formulations were checked for cytotoxicity by a CellTiter-Glo® assay (Promega, Leiden, The  
Netherlands) prior to uptake and silencing experiments.  
 
2.6. Cell line and culture conditions 
Cell culture experiments were performed using a human lung epithelial cell line (H1299) that stably 
expresses eGFP (H1299_eGFP), obtained from the lab of Prof. Camilla Foged (Department of 
Pharmacy, University of Copenhagen, Denmark). H1299_eGFP cells were cultured in RPMI 1640 
supplemented with 2 mM glutamine, 10 % fetal bovine serum and 100 U/mL penicillin/streptomycin at 
37 °C in a humidified atmosphere containing 5 % CO2. Cells were passaged every 3 days using 0.25 % 
trypsin-ethylenediaminetetraacetic acid (EDTA) solution in order to maintain sub-confluency. 
H1299_eGFP cells were treated with medium containing 1 mg/mL Geneticin® once per month for eGFP 
transgene selection. All materials were purchased from Gibco®-Life Technologies (Grand Island, NY, 
USA), except for the serum, which was delivered by HycloneTM (GE Healthcare, Machelen, Belgium). 
 
2.7. Quantification of in vitro cellular siRNA internalization in H1299_eGFP cells by flow 
cytometry 
To quantify the cellular uptake of siRNA by flow cytometry, H1299_eGFP cells were seeded in 24-
well plates (Greiner Bio-One GmbH, Kremsmünster, Austria) at a density of 2 x 104 cells/cm2 and left to 
settle overnight. NGs were loaded with different amounts of siCTRL:siCy5 (100:0.75 mol%) and coated 
with Curosurf® or a proteolipid mixture using the coating procedure described above. After 5-fold dilution 
in Opti-MEM® (final NG concentration of 30 µg/mL), the particles were incubated with the cells for 4 h 
(37 °C, 5 % CO2). Following incubation, the cells were washed with dextran sulfate sodium salt 
(0.1 mg/mL in PBS) to remove cell surface-bound fluorescence. Next, the cells were harvested by 
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trypsinization (trypsin/EDTA 0.25 %), resuspended in 250 µL flow buffer (PBS supplemented with 1 % 
bovine serum albumin and 0.1 % sodium azide) and incubated on ice until flow cytometry analysis. 
Transfections were performed in technical triplicate per independent biological repeat and a minimum 
of 104 cells was analyzed in each measurement, using a FACSCaliburTM flow cytometer (BD 
Biosciences, Erembodegem, Belgium). Data analysis was performed using the FlowJoTM analysis 
software (Treestar, Costa Mesa, USA). 
 
2.8. Quantification of in vitro eGFP silencing in H1299_eGFP cells by flow cytometry 
H1299_eGFP cells were seeded in 24-well plates (Greiner Bio-One GmbH; 1.85 x 104 cells/cm2). 
NGs were loaded with variable amounts of siCTRL or siEGFP. Next, the siNGs were coated with 
Curosurf® or a proteolipid mixture using the coating procedure described above. After 5-fold dilution in 
Opti-MEM® (final NG concentration of 30 µg/mL), the particles were incubated with the cells for 4 h 
(37 °C, 5 % CO2). Following incubation, non-internalized nanoparticles were washed away with PBS 
and the cells were incubated with 1 mL fresh cell culture medium for 48 h. The cells were then prepared 
for analysis by flow cytometry as described above. Transfections were performed in technical triplicate 
per independent biological repeat and a minimum of 2 x 104 cells was analyzed in each measurement 
as described above. 
 
2.9. Ex vivo quantification of siRNA uptake by different immune cell types and assessment of 
acute in vivo toxicity and cellular influx in naive BALB/c mice 
Female BALB/c mice were purchased from Charles River Italy and housed under specific pathogen-
free conditions in individually ventilated cages in a controlled 12 h day-night cycle and given food and 
water ad libitum. All mice were 8 weeks old at the start of the experiments. All procedures involving 
animals were approved by the local Ghent University ethics committee (accreditation nr. LA1400536, 
Belgium), in accordance with European guidelines. The (proteolipid coated) siNGs and control 
suspensions for administration were prepared as described above, followed by a 2-fold dilution in 2 
times concentrated PBS. Per mouse, a dose of 100 µg NG loaded with 1 pmol siCy5 per µg NG was 
administered. Mouse tracheal aspiration was used for NP administration. [36] Briefly, after sedation with 
isoflurane (inhalation at 4 % for induction and 3 % for maintenance), individual mice were placed in a 
near-vertical position. The animal’s tongue was extended with lined forceps, and 80 µL of the NP 
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suspension was instilled posterior of the pharynx. The tongue was held in position until the dispersion 
was inhaled into the lungs. Control mice were administered 80 µL of PBS. 24 h after NP administration, 
bronchoalveolar lavage (BAL) isolation was performed as described by Van Hoecke et al. [37] The mice 
were euthanized by intraperitoneal injection of a lethal dose of Nembutal® (pentobarbital, 200 mg/kg in 
PBS; Ceva, Brussels, Belgium). Immediately after euthanization, a lavage cannula was placed into the 
trachea through a small incision. The lungs were flushed once with 1 mL Ca2+- and Mg2+- free Hank’s 
balanced salt solution (HBSS; InvitrogenTM-Life Technologies), supplemented with 0.05 mM EDTA 
(Sigma-Aldrich). The obtained BAL was subsequently centrifuged (400 g, 7 min, 4 °C), to separate the 
cellular fraction from the supernatant. The BAL cellular fraction was resuspended in PBS. The different 
cell types isolated from the BAL fluids were typed and quantified by flow cytometry. Fc-blocked (1 µg/ml; 
clone 2.4G2; BD Biosciences, San Jose, CA, USA) cells were stained with anti-mouse major 
histocompatibility complex (MHC) class II-eFluor 450 (0.4 µg/mL, clone M5/114.15.2; eBioscience, San 
Diego, CA, USA), CD3ε-Alexafluor 488 (1 µg/mL, clone245-2C11; BD Biosciences), SiglecF-
phycoerythrin (1 µg/mL, clone E50-2440; BD Biosciences), CD4-peridinin-chlorophyll protein complex 5 
(1 µg/mL, clone RM4-5; BD Biosciences), CD8-PE-Cy®7 (1 µg/mL, clone 53-6.7; BD Biosciences), 
CD11b-allophycocyanin-Cy®7 (1 µg/mL, clone M1/70; BD Biosciences). A live-dead staining was added 
to exclude dead cells from the analysis. All samples were measured on a FACS LSRII flow cytometer 
(BD Biosciences) and acquired using FACSDiva software (BD Biosciences). Within the single cells that 
were alive, CD4+ and CD8+ T lymphocytes were identified as CD3ε+CD4+ and CD3ε+CD8+ cells, 
respectively. Alveolar macrophages were identified within the CD3ε-Cd11c+ cell population based on 
their high expression of Siglec-F. Finally neutrophils and eosinophils were identified as CD3ε-CD11c-
Siglec-F-CD11b+ and CD3ε-CD11c-Siglec-F+CD11b+ cells respectively in the remaining cell population. 
Data analysis was performed using the FlowJoTM analysis software (Treestar, Costa Mesa, USA). The 
BAL supernatant was quantified for murine interleukin 1α (IL-1α), interleukin 1β (IL-1β), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interleukin 6 (IL-6), tumor necrosis factor α (TNFα), 
macrophage inflammatory protein 1α (MIP-1α), KC and monocyte chemoattractant protein 1 (MCP-1) 
with a Bio-Plex® Suspension array system (Biorad, Hercules, USA) according to manufacturer’s 
specifications. The analytes were measured with a Luminex protein array reader and Bio-Plex® manager 
software version 5.0 (Bio-Rad Laboratories), using recombinant standards (Bio-Rad Laboratories). For 
data analysis, a 5-parameter logistic curve fit was applied to each standard curve and sample. In 
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addition, the supernatant was quantified for mouse albumin using a Mouse Albumin ELISA Kit (Genway 
Biotech, San Diego, CA, USA).  
 
2.10. In vivo TNFα silencing in murine acute lung injury (ALI) model 
Female BALB/c mice were purchased from Charles River Italy and kept in the same conditions as 
described above. The (proteolipid-coated) siNGs and control suspensions for administration were 
prepared as described above, followed by a 2-fold dilution in 2 times concentrated PBS. Per mouse, a 
dose of 100 µg NG loaded with 1 pmol TNFα targeting siRNA (siTNFα) or siCTRL per µg NG was 
administered. Mouse tracheal aspiration [36] was used for NP administration as described above. 24 h 
after NP administration, mice received a lipopolysaccharide (LPS) dose of 5 µg in 80 µL PBS via tracheal 
aspiration. [36] 48 h after NP administration, thus 24 h after LPS administration, BAL isolation [37] was 
performed. The obtained BAL was subsequently centrifuged (400 g, 7 min, 4° C), to separate the cellular 
fraction from the supernatant. The BAL supernatant was quantified for murine TNFα with a Bio-Plex® 
Suspension array system (Biorad, Hercules, USA) as previously described.  
 
2.11. Statistical analysis 
All in vitro experiments were performed in technical triplicate and as 3 independent biological repeats 
(n=3), unless otherwise stated. All in vivo experiments were performed as 4 biological replicates (n=4). 
All data are presented as mean ± standard deviation (SD). Statistical analysis was performed via One-
way ANOVA followed by a Tukey’s multiple comparison test, using GraphPad Prism software version 6. 















3. RESULTS AND DISCUSSION 
 
3.1. Identification of Curosurf® components responsible for enhanced siRNA delivery  
We recently reported on the unanticipated finding that the decoration of siRNA-loaded dextran 
nanogels (siNGs) with a clinically used pulmonary surfactant (PS) from porcine origin (Curosurf) 
substantially enhanced cellular siRNA delivery both in vitro [9] and in vivo. [10] 
 
Comparable to native human PS, the most abundant component of the (phospho)lipid fraction in 
Curosurf® is 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), representing ~40-50 wt% of the total 
surfactant mass. Other important phospholipids include (unsaturated) PCs and the anionic 
phosphatidylglycerol (PG). In contrast to native human PS,  cholesterol is removed during production of 
Curosurf®, as well as the hydrophilic surfactant proteins (SPs), i.e. SP-A and SP-D. [17]  
Figure 1. Biological activity of siNGs coated with surfactant protein containing proteolipid mixtures. (a) Schematic illustration of the 
(proteo)lipid coated siRNA-loaded nanogels (siNGs). Evaluation of (b) cellular uptake and (c) gene silencing potential of siNGs in H1299_eGFP 
cells determined via flow cytometry. The siNGs were layered with Curosurf® (coated siNGs (CS)) or DPPC:POPC:eggPG (50:35:15 wt%; coated 
siNGs (LIP)). In this LIP outer layer, SP-B (0.4 wt%) and/or SP-C (0.7 wt%) were incorporated. In the uptake experiments, NGs were loaded with 
fluorescently labeled control siRNA (siCy5), for which values of the coated formulations are shown relative to the maximal amount of particles 
taken up, i.e. for uncoated siNGs (100 %). The eGFP expression of the cells treated with eGFP-targeting siRNA (siEGFP) was normalized to the 
expression of cells treated with control siRNA (siCTRL). All experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA 
concentration (50 nM) (technical triplicate). 
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To evaluate the contribution of the remaining hydrophobic SPs to the PS-enhanced siRNA delivery, 
siNGs were initially coated with a mixture of abundant PS phospholipids, i.e. DPPC, 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC) and L-α-phosphatidylglycerol (eggPG) in a 50:35:15 weight ratio. 
This synthetic lipid mixture was supplemented with SP-B and/or SP-C isolated from Curosurf®, using 
weight ratios documented in the literature (i.e. 0.4 wt% SP-B and 0.7 wt% SP-C) (Figure 1a). [18] 
As illustrated in Figure 1b, the presence of either a Curosurf® or simplified (proteo)lipid outer layer 
markedly reduced the uptake of siNGs in lung epithelial cells (H1299_eGFP), which was most 
pronounced for the synthetic compositions. Remarkably and in agreement with our earlier observations, 
[9] Curosurf® (CS) coated siNGs retained their gene silencing potential, despite the lower uptake. 
However, in the absence of SPs (i.e. siNGs coated with the DPPC:POPC:eggPG (LIP) mixture only) 
and in line with earlier data using CS as coating material, [19] this impaired cellular internalization also 
abrogated the gene silencing potential of the siNGs (Figure 1c). Interestingly, despite a similar reduction 
in cellular siRNA uptake, the addition of 0.4 wt% SP-B resulted in 40 % eGFP gene suppression, an 
effect that could not be mimicked by SP-C. Although the extent of eGFP silencing obtained by the 
Curosurf® coating could not be reached, these pilot data clearly suggest that SP-B is a key molecular 
determinant for the enhanced siRNA delivery effects initially observed earlier for Curosurf®. [9] This 
finding is more thoroughly investigated in the experiments below. 
 
3.2. Impact of lipid composition on SP-B functionality 
As it is known that the hydrophobic SP-B and SP-C preferentially localize in a liquid state lipid 
environment, we compared the efficiency of siNGs layered with DPPC:eggPG (85:15 wt%) or 
DOPC:eggPG (85:15 wt%) (Figure 2). These binary phospholipid mixtures are a combination of the 
negatively charged eggPG, required for coating of the cationic siNGs via electrostatic interaction, with a 
fully saturated (DPPC, phase transition temperature (Tm) = 41°C) or unsaturated (DOPC, Tm = -17°C) 
phosphatidylcholine (PC). All coated formulations have an average size <200 nm, a zeta-potential < 
-20 mV and a PDI <0.25, indicating colloidal stability (Figure S2). In addition, transmission electron 
cryomicroscopy (cryoTEM) imaging confirmed the anticipated core-shell morphology  
(Figure S3). As expected, independent of both the applied phospholipid mixture and the presence of 
SP-B, the cellular internalization of siNGs was markedly reduced after coating (>90 %) 
(Figure 2a). The latter resulted in negligible gene knockdown in the absence of SP-B (Figure 2b). 
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However, supplementing the DPPC:eggPG coat with SP-B (0.8 wt%) generated a similar level of 
knockdown compared to the previous results on DPPC:POPC:eggPG (Figure 1c).  
Analogous to the data presented in Figure 1, the addition of SP-C to the DOPC:eggPG coat did not 
improve eGFP silencing and thus siRNA delivery (Figure 3), confirming that, independent of the 
saturation level of the phospholipid coat, SP-B is responsible for the enhanced cytosolic delivery of 
siRNA. From a biophysical point of view, SP-B is essential to maintain proper lung function by promoting 
lipid adsorption onto the alveolar air-liquid interface and stabilization of multilamellar surfactant films 
during expansion-compression breathing cycles. [22, 23]  
Figure 2. Impact of the main phospholipid in the outer proteolipid layer on siNGs biological activity. Evaluation of (a) cellular uptake 
and (b) gene silencing potential of siNGs in H1299_eGFP cells determined via flow cytometry. The siNGs were layered with DPPC:eggPG 
(85:15 wt%) or DOPC:eggPG (85:15 wt%) in the absence or presence of SP-B (0.8 wt%). In the uptake experiments, NGs were loaded with 
fluorescently labeled control siRNA (siCy5), for which values of the coated formulations are shown relative to the maximal amount of particles 
taken up, i.e. for uncoated siNGs (100 %). The eGFP expression was normalized to the expression of cells treated with control siRNA (siCTRL). 
All experiments were performed with a fixed NG concentration (30 µg/mL) and siRNA concentration (50 nM) (n=2; * p ≤ 0.05, *** p ≤ 0.001). 
 
Figure 3. Biological activity of siNGs coated with a DOPC:eggPG mixture supplemented with different surfactant protein 
combinations. Evaluation of (a) cellular uptake and (b) gene silencing potential of siNGs in H1299_eGFP cells determined via flow cytometry. 
The siNGs were layered with Curosurf® (coated siNGs (CS)) or DOPC:eggPG (85:15 wt%; coated siNGs (LIP)). In this LIP outer layer, SP-B 
(0.4 wt%) and/or SP-C (0.7 wt%) were incorporated. In the uptake experiments, NGs were loaded with fluorescently labeled siRNA (siCy5), for 
which values of the coated formulations are shown relative to the maximal amount of particles taken up, i.e. for uncoated siNGs (100 %). The 
eGFP expression was normalized to the expression of cells treated with control siRNA (siCTRL). All experiments were performed with a fixed 




It is believed that this interfacial activity is linked to both SP-B’s fusogenic properties and its ability to 
facilitate close contact between neighboring membranes. The presence of SP-B in the surfactant outer 
shell of the nanocomposites might therefore induce fusion of the outer layer with the target cell plasma 
membrane and/or endolysosomal membrane, thus improving cytosolic siRNA delivery. [20, 21] 
Remarkably, replacing the rigid DPPC by the more fluid DOPC significantly promoted gene silencing, 
this time reaching comparable levels of knockdown as measured for uncoated siNGs (Figure 2b), albeit 
with a minor reduction in cell viability (Figure S4). It is conceivable that a more fluid state (phospho)lipid 
crystalline environment in the particle coat might further facilitate SP-B mediated intermembrane 
interactions, given a less dense phospholipid packing and thus less resistance for lateral diffusion in the 
membrane. In addition, a recent model has suggested that SP-B organizes in the form of supramolecular 
multimers to support its function (e.g. membrane fusion), which also likely requires lateral mobility in its 
(phospho)lipid environment. [24] Possibly, these multimers are also important for siRNA delivery. 
Unraveling the mechanism of action of SP-B will be the subject of future investigations.  
 
3.3. Evaluation of SP-B from different origins and impact of SP-B concentration 
To further validate the key role of SP-B, we tested different batches of SP-B, i.e. isolated from 
Curosurf® or freshly extracted porcine lungs (n=3). Independent of the source, the inclusion of SP-B in 
the DOPC:eggPG outer layer similarly reduced the cellular internalization but maintained the gene 
silencing potential of the proteolipid coated siNGs in H1299_eGFP cells, which underscores the validity 
of our findings (Figure 4a and 4b). In this context, we also investigated if we could amplify the effect by 
increasing the concentration of SP-B. Higher fractions of SP-B in the outer lipid layer seemed to further 
reduce cellular uptake of siRNA by the H1299_eGFP cells. Hence, the gene silencing potential was also 
slightly less pronounced. Nevertheless, even at 1.6 wt% SP-B, 60 % eGFP silencing is obtained with 10 
nM of siRNA despite the ~25-fold reduction in cellular siRNA dose relative to uncoated siNGs  
(Figure 4e and 4f). Also, when decreasing the SP-B fraction in the proteolipid coat, a significant 
reduction in eGFP knockdown was observed at 0.1 wt% of SP-B (Figure 4c and 4d). These data indicate 
that a minimum concentration of SP-B between 0 and 0.1 wt% is required to promote gene silencing. 
Remarkably, as little as 0.2 wt% of SP-B resulted in maximal silencing under the given experimental 





Figure 4. Impact of SP-B source and concentration on the biological activity of the proteolipid coated siNGs. Evaluation of (a) cellular 
uptake and (b) gene silencing potential of coated siNGs incorporating SP-B isolated from different sources. The siNGs were layered with 
DOPC:eggPG (85:15 wt%). SP-B (0.4 wt%) isolated from 3 different native porcine lungs (SP-B 1; SP-B 2; SP-B 3) or isolated from Curosurf® 
(SP-B 4) was incorporated in the outer lipid layer (technical triplicate). Evaluation of (c),(e) cellular uptake and (d),(f) gene silencing potential of 
coated siNGs incorporating different concentrations of SP-B. The siNGs were layered with DOPC:eggPG (85:15 wt%) and SP-B isolated from 
native porcine lungs. In the uptake experiments, NGs were loaded with fluorescently labeled siRNA (siCy5), for which values of the coated 
formulations are shown relative to the maximal amount of particles taken up, i.e. for uncoated siNGs (100 %). The eGFP expression was 
normalized to the expression of cells treated with control siRNA (siCTRL). All experiments were performed with a fixed NG concentration 









Figure 5. Evaluation of cytokine, chemokine and albumin levels upon administration of different NP compositions. Different NPs were 
administered to naive BALB/c mice and after 24 h, BAL was extracted and tested for IL-1α, IL-1β, GM-CSF, IL-6, TNFα, MIP-1α, KC and MCP-





3.4. In vivo toxicity of proteolipid coated siNGs in naive BALB/c mice 
Following our promising in vitro results, we aimed to assess whether the enhanced intracellular 
siRNA delivery by SP-B in proteolipid coated siNGs could be reproduced in vivo. 
Since pulmonary administration of nanoparticles (NPs) can induce inflammation, it is of particular 
interest to first evaluate the possible pro-inflammatory effects of NPs following inhalation therapy. To 
this end, the levels of distinct cyto- and chemokines were quantified in bronchoalveolar lavage (BAL) 
fluid of naive, specific pathogen free housed BALB/c mice that had been treated with the different NPs 
via tracheal aspiration. 
Compared to PBS treatment, all formulations significantly induced secretion of IL-1α, GM-CSF, IL-6, 
MIP-1α and KC, whereas for IL-1β, TNFα and MCP-1 this was only the case for one or both DOPC-
containing formulations, suggesting a minor inflammatory response due to a phospholipid imbalance in 
the murine surfactant by administration of the non-endogenous DOPC (Figure 5). Indeed, it is known 
that the surfactant lipid composition plays an important role in many processes at the host-environment 
interface, including pulmonary inflammation. [38] However, the measured levels for IL-6 and TNFα 
compared to PBS were not correlated with excessive inflammation according to the literature. [25, 26] 
The cellular infiltrate in BAL fluid following NP administration did not reveal major differences between 
the formulations and PBS treated control mice. As expected, alveolar macrophages were the 
predominant cell type occurring in the BAL (Figure S5). All formulations except the siNGs coated with 
a mixture of DPPC, eggPG and SP-B significantly elevated albumin levels, which is used as a measure 
of inflammation-associated capillary permeabilization. The highest albumin levels were detected for 
mice treated with siNGs coated with an SP-B supplemented DOPC:eggPG coat, which is in line with the 
reduced cell viability observed for this formulation in vitro (Figure S4). Nevertheless, the maximally 
measured 2-fold increase compared to PBS is indicative of an acceptable degree of toxicity. [27] 
Importantly, when combining DPPC with SP-B as proteolipid coat, no elevated albumin levels were 
detected. Altogether, these data indicate that selecting a formulation that more closely mimics the 
endogenous surfactant composition is preferred from a toxicological point of view. 
 
3.5. In vivo uptake of proteolipid coated siNGs by respiratory immune cells in naive BALB/c mice 
Next, it was evaluated to what extent the nanocomposites were internalized by respiratory immune 
cells following tracheal aspiration in naive mice. The vast majority of Cy5-labeled siRNA delivered by 
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NPs is taken up by resident alveolar macrophages (rAMs), neutrophils and eosinophils, while little Cy5 
fluorescence was detected in T cells. Of note, in stark contrast to our in vitro observations, (proteo)lipid 




3.6. TNFα silencing in a murine lipopolysaccharide-induced acute lung injury model 
It was shown previously that (Curosurf®-coated) siNGs are able to transfect rAMs and induce 
sequence-specific knockdown of an endogenous target. [18] Given the predominance of rAMs and the 
high and equivalent uptake by this cell type observed for all NPs independent of the proteolipid coat, a 
murine lipopolysaccharide (LPS)-induced acute lung injury (ALI) model was chosen to evaluate the 
impact of SP-B in a phospholipid type coating on in vivo siRNA delivery. In ALI, rAMs play a central role  
in pulmonary inflammation, in particular through their induced secretion of TNFα as an early mediator 
of the underlying immunologic cascade. [28-30] It has been shown by several groups that 
downregulation of TNFα in the microenvironment of the lung is indeed associated with reduced lung 
injury caused by ALI, highlighting its value as a target for therapeutic intervention. [4],[31] Naive BALB/c 
mice were prophylactically treated with the different NP formulations loaded with a TNFα targeting siRNA 
(siTNFα), 24 h prior to stimulation with LPS via tracheal aspiration (Figure 7a). LPS exposure increased 
TNFα levels >20-fold compared to PBS control and NP administration in naive BALB/c mice (Figure S6 
and Figure 5).  
Figure 6. In vivo siCy5 delivery to different respiratory immune cells. Resident alveolar macrophages (rAMs), eosinophils, 
neutrophils, CD4+ T cells and CD8+ T cells were evaluated for geometric mean fluorescence intensity (MFI), 24 h after treatment 
with a fixed NG dose (100 µg) loaded with 1 pmol siCy5 per µg NGs and coated with different proteolipid compositions (n=4, all 




Remarkably, in contrast to our in vitro observations that were based on eGFP silencing in an 
H1299_eGFP cell line, no TNFα knockdown could be measured for uncoated siNGs or siNGs layered 
with an SP-B embedding DOPC:eggPG coat (Figure 7b). Although the more rigid DPPC:eggPG coat 
was less efficient in promoting siRNA delivery in vitro, only this formulation was able to reduce the 
relative TNFα levels in BAL of LPS exposed mice when supplemented with SP-B.  
Importantly, the formulation with DPPC as main phospholipid was also best tolerated following  
in vivo administration (Figure 5). Differences in NP stability in the lung extracellular fluid, more 
specifically lipid mixing of the more fluid DOPC composed proteolipid shell with the endogenous 

















Figure 7. Relative TNFα silencing in a murine acute lung injury (ALI) model. (a) Schematic representation of the executed 
experiment. (b) TNFα levels were quantified in BAL fluid extracted 24 h after LPS stimulation and thus 48 h after instillation of different 
siCTRL and siTNFα loaded NPs. The TNFα levels obtained with siTNFα loaded siNGs was normalized to the levels in BAL of mice that 
had received control siRNA (siCTRL). Mice were treated with a fixed NG dose (100 µg) loaded with 1 pmol siTNFα or siCTRL per µg NG 




alveolar macrophages, could explain the observed lack of in vitro-in vivo correlation regarding the 
optimal phospholipid composition, although this needs further experimental clarification. Most 
importantly, in line with our in vitro results, we were able to demonstrate that inclusion of SP-B in the 
particle proteolipid coating is also required for detectable sequence-specific silencing of TNFα. 
Of note, in this ALI model absolute TNFα levels for most NPs were found to be equal to or exceed 
the value for PBS treated mice as shown in Figure S6, reducing the intrinsic therapeutic value of these 
formulations in this particular model. Only the DPPC:eggPG coated formulation containing active siRNA 
and SP-B reduced TNFα levels with 20% compared to PBS control. The observed TNFα upregulation 
might indicate that ALI mice are more susceptible to NP-induced effects, as opposed to naive mice. 
Along with increased neutrophil influx and granulocyte chemotaxis, it has been shown that inhalation of 
some NPs by LPS-exposed mice indeed can be associated with elevated TNFα levels and in general 
aggravation of inflammation. The latter underscores the importance of finding the optimal balance 
between NP-mediated drug delivery and NP-induced off-target effects. [32] In this context, further 
histopathological scoring of inflammation could add valuable information on the actual toxicity and 



















We have identified surfactant protein B (SP-B) as a naturally-derived siRNA delivery enhancer when 
reconstituted in proteolipid coated siRNA loaded nanogels (siNGs). The beneficial effect of SP-B on 
siRNA delivery and resulting gene silencing could be observed in an in vitro lung epithelial cell line and 
in vivo in a lipopolysaccharide-induced acute lung injury model (ALI), targeting resident alveolar 
macrophages, albeit that a distinct phospholipid composition was required. The successful proof-of-
concept data presented here could pave the way for evaluation of the SP-B delivery platform for 
therapeutic intervention in various pulmonary pathologies or for identification of key molecular drug 
targets. Future work will evaluate the presented SP-B centered delivery platform in distinct models of 
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7. SUPPLEMENTARY  
 
Scheme S1. Graphical representation of the siRNA delivery efficacy guided by (a) siRNA-loaded nanogels and (b) 
Curosurf® coated siRNA-loaded nanogels. As reported previously, [9] the (1) cellular internalization of the nanogels is 
significantly reduced in the presence of a Curosurf® outer layer. Remarkably, despite poor intracellular siRNA uptake, the (2) gene 
silencing potential  was maintained, suggesting that the Curosurf outer layer promotes the cytosolic delivery of siRNA e.g. through 
improved endosomal escape. In this work, we aim to identify the molecular components in Curosurf responsible for this enhanced 





Figure S1.  In vitro TNFα knockdown by a siTNFα set of four in (LPS stimulated) MH-S cells. All experiments were performed 


































Figure S2. (a) Hydrodynamic diameter and (b) zeta potential of (coated) nanogel (NG) formulations as measured by Dynamic 
Light Scattering (DLS). All particles were prepared under the same experimental conditions as those used for in vitro and in vivo 
experiments. Measurements were performed at room temperature in HEPES buffer (pH 7.4, 20 mM). PDI for all samples was between 








Figure S3. Transmission electron cryomicroscopy images of different nanoformulations. The figure shows a comparison of (a) 
uncoated; (b) Curosurf® coated; (c) DPPC:eggPG:SP-B coated and (d) DOPC:eggPG:SP-B coated siRNA-loaded nanogels (siNGs). 











Figure S4. In vitro cell viability of different formulations. H1299_eGFP cells were incubated with different NP in the same 
conditions as uptake and silencing experiments. 24 h after incubation, luminescence was measured per condition via a CellTiter Glo® 
assay and viability was determined as percentage of luminescent signal relative to non-treated cells (NTC) for each formulation. 













Figure S5. Immune cell infiltration after NP administration in naive BALB/c mice. The cellular fraction of BAL fluid as quantified 
for resident alveolar macrophages (rAMs), eosinophils, neutrophils, CD4+ T cells and CD8+ T cells via flow cytometry, 24 h after 














































Figure S6. Absolute TNFα levels in a murine acute lung injury (ALI) model. TNFα levels were quantified in BAL fluid extracted 
24 h after LPS stimulation and thus 48 h after instillation of different siCTRL (black bars) and siTNFα (white bars) loaded NPs (Figure 
7a). Mice were treated with a fixed NG dose (100 µg) loaded with 1 pmol siTNFα or siCTRL per µg NG. PBS was administered as a 





















DPPC DOPC POPC eggPG SP-B SP-C Figure 
DPPC:POPC:eggPG 50  35 15   1 
DPPC:POPC:eggPG + 
SP-B 






49.65  34.76 14.9  0.7 1 
 
DPPC:POPC:eggPG + 
SP-B + SP-C 
49.45  34.62 14.84 0.4 0.7 1 
DPPC:eggPG 
 








84.66   14.94 0.4  5,6,7 
 
DPPC:eggPG  
+ SP-B (0.8 wt%) 








 84.41  14.9  0.7 3 
 
DOPC:eggPG  
+ SP-B + SP-C 
 84.07  14.84 0.4 0.7 3 
 
DOPC:eggPG  
+ SP-B (0.1 wt%) 
 84.92  14.99 0.1  4 
 
DOPC:eggPG  
+ SP-B (0.2 wt%) 
 84.83  14.97 0.2  4 
 
DOPC:eggPG  
+ SP-B (0.3 wt%) 
 84.75  14.96 0.3  4 
 
DOPC:eggPG  
+ SP-B (0.8 wt%) 
 84.32  14.88 0.8  2,4 
 
DOPC:eggPG  
+ SP-B (1.6 wt%) 
 83.64  14.76 1.6  4 
Table S1. Overview of compositions of different proteolipid coating mixtures for siNGs.  All numbers are expressed as wt% 
of the total mixture. 
 
